Forbion-backed biotech Progentos debuts with $65M for MS drug

May 20, 2024 · Forbion-backed biotech Progentos debuts with $65M for MS drug Progentos says the money will go toward expanding its pipeline and pushing an experimental treatment for …

CouponFollow Extension

$65
OFF

Forbion-backed Biotech Progentos Debuts With $65M For MS Drug

2 days from now

May 20, 2024 · Forbion-backed biotech Progentos debuts with $65M for MS drug Progentos says the money will go toward expanding its pipeline and pushing an experimental treatment for …

biopharmadive.com

$65
OFF

Progentos Therapeutics Closes $65 Million Series A Financing To …

2 days from now

WATERTOWN, Mass., May 20, 2024--Progentos Therapeutics, a biotech company addressing the critical unmet need to regenerate myelin and restore function for patients with Multiple …

yahoo.com

$65
OFF

Forbion-backed Biotech Progentos Debuts With $65M For MS Drug

2 days from now

May 20, 2024 · Progentos says the money will go toward expanding its pipeline and pushing an experimental treatment for multiple sclerosis through "proof of concept” testing. Forbion, a well …

alphastox.com

$65
OFF

Biotech Firm Progentos, Supported By Forbion, Launches With A $65 ...

2 days from now

Forbion-backed Biotech Progentos Debuts with $65M for MS Drug. In a significant boost to the field of neurodegenerative diseases, Progentos, a newly formed biotechnology company, has …

arsenallifescience.com

$65
OFF

Progentos Therapeutics Closes $65 Million Series A ... - Neuro …

2 days from now

May 20, 2024 · The series A financing was led by Netherlands-based Forbion which was joined by Alta Partners, Mission BioCapital, Longwood Fund, and Dolby Family Ventures. “ We are truly …

neuro-central.com

$65
OFF

Progentos Emerges With $65M For Multiple Sclerosis Trials With

2 days from now

May 20, 2024 · A new biotech emerged to take forward the lead preclinical work developed by Frequency Therapeutics, a regenerative medicines company that gave up its Nasdaq spot in a …

bcbn.org

$65
OFF

Progentos Therapeutics Closes $65M Series A Financing - FinSMEs

2 days from now

May 20, 2024 · Progentos Therapeutics, a Watertown, MA-based biotech company addressing the need to regenerate myelin and restore function for patients with Multiple Sclerosis (MS) …

finsmes.com

$65
OFF

Progentos Therapeutics: $65 Million Raised To Address Unmet …

2 days from now

May 20, 2024 · Progentos Therapeutics, a biotechnology company addressing the unmet need to regenerate myelin and restore function for patients with Multiple Sclerosis (MS) and other …

pulse2.com

$65
OFF

Forbion Capital Partners. (5/21/24). "Press Release: Forbion Leads …

2 days from now

Forbion, a leading life sciences venture capital firm, announced today the $65 million Series A financing of Progentos Therapeutics (“Progentos”), a new biotech company focused on the …

life-sciences-europe.com

$65
OFF

Progentos Launches With $65M For MS Drug Development

2 days from now

May 20, 2024 · Home News Progentos launches with $65M for MS drug development Progentos launches with $65M for MS drug development. May 20, 2024 BCBN News, ... Forbion-backed …

bcbn.org

$65
OFF

Progentos Therapeutics Closes $65 Million Series A Financing To …

2 days from now

WATERTOWN, Mass., May 21, 2024-- Progentos Therapeutics, a biotech company addressing the critical unmet need to regenerate myelin and restore function for patients with Multiple …

vcaonline.com

$65
OFF

Forbion-backed Biotech Progentos Debuts With $65M For MS Drug

2 days from now

May 21, 2024 · Forbion, a well-known backer of life sciences startups, is leading an investment round for a newly launched biotechnology company focused on diseases that affect nerve …

autaski.com

FAQs about Forbion-backed biotech Progentos debuts with $65M for MS drug Coupon?

Why did progentos receive $65 million in funding?

Progentos Therapeutics said it received $65 million in funding to support the development of myelin regeneration medications able to restore function in people with multiple sclerosis (MS) and other diseases marked by myelin loss. ...

What does progentos Therapeutics do?

WATERTOWN, Mass., May 20, 2024 -- ( BUSINESS WIRE )--Progentos Therapeutics, a biotech company addressing the critical unmet need to regenerate myelin and restore function for patients with Multiple Sclerosis (MS) and other demyelinating diseases, today announced its launch and the closing of a $65 million series A round. ...

Could progentos revolutionize the standard of care for MS patients?

The involvement of prominent investors underscores the confidence in Progentos’ scientific and entrepreneurial leadership. As the company advances its MS program into human proof of concept studies, it could potentially revolutionize the standard of care for millions suffering from MS and other demyelinating diseases. ...

Who invested in progentos Therapeutics?

Progentos Therapeutics shared news of its Series A investment on Monday. The venture capital round was led by Netherlands-based Forbion and supported by Alta Partners, Mission BioCapital, Longwood Fund and Dolby Family Ventures. ...

Who financed progentos?

The series A financing was led by Netherlands-based Forbion which was joined by Alta Partners, Mission BioCapital, Longwood Fund, and Dolby Family Ventures. "We are truly excited to be part of Progentos’ journey towards delivering potentially disease-modifying drugs for diseases like multiple sclerosis, diseases with high unmet clinical needs. ...

Does progentos remyelination work?

The company’s innovative approach to remyelination through first-in-class small molecules holds promise for addressing a critical unmet need in MS therapy. The involvement of prominent investors underscores the confidence in Progentos’ scientific and entrepreneurial leadership. ...